Switch Therapeutics is developing biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system diseases. Switch’s Conditionally Activated siRNA (CASi), developed at Caltech, Harvard Medical School, and City of Hope, combines the best attributes of antisense oligonucleotides (ASO) and siRNAs. Switch is initially focusing on developing our precision medicines for central nervous system (CNS) diseases with high unmet need.